Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OneRIF: High-Dose Rifampicin for Pulmonary TB
NCT02153528Phase 3Completed
- Sponsor
- Damien Foundation
- Start
- Nov 2014
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rifampicin in pulmonary tuberculosis (TB), sponsored by Damien Foundation. Started Nov 2014; status: completed.
02
Drugs
rifampicin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT02153528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02153528.